These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 34393221)

  • 1. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
    Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
    Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
    [No Abstract]   [Full Text] [Related]  

  • 3. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms.
    Kuroda N; Tsutsui M; Iguchi M; Nobuoka E; Uehara T; Sonobe Y; Morinaga Y; Shibuya S; Oda W; Yanai H; Kawada C; Karashima T; Yamasaki I; Inoue K; Nagashima Y
    Ann Diagn Pathol; 2020 Dec; 49():151599. PubMed ID: 32977234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
    Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
    Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
    Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
    Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
    Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
    Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of Clinicopathological, immunohistochemistry and molecular detection in the diagnosis of fumarate hydratase-deficient uterine leiomyomas.
    Zhang X; Wang C; Shen D
    Pathol Res Pract; 2024 Jan; 253():154916. PubMed ID: 38029712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidetector CT Characteristics of Fumarate Hydratase-Deficient Renal Cell Carcinoma and Papillary Type II Renal Cell Carcinoma.
    Yang L; Li XM; Hu YJ; Zhang MN; Yao J; Song B
    Korean J Radiol; 2021 Dec; 22(12):1996-2005. PubMed ID: 34668351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fumarate hydratase-deficient renal cell carcinoma: an oncology care institutional experience.
    Kamboj M; Gupta G; Pasricha S; Mehta A; Rawal S; Singh A; Sharma A; Durga G; Bansal D; Diwan H
    APMIS; 2024 Aug; 132(8):544-552. PubMed ID: 38775301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
    Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
    Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
    J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-evaluation of 33 'unclassified' eosinophilic renal cell carcinomas in young patients.
    Li Y; Reuter VE; Matoso A; Netto GJ; Epstein JI; Argani P
    Histopathology; 2018 Mar; 72(4):588-600. PubMed ID: 28898443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma.
    Kwon R; Argani P; Epstein JI; Lombardo KA; Wang X; Pierorazio PM; Mehra R; Matoso A
    Am J Surg Pathol; 2021 Apr; 45(4):450-462. PubMed ID: 33239504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Rare Case of Synchronous Fumarate Hydratase-Deficient Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma With Fumarate Hydratase and von Hippel-Lindau Gene Mutations: A Clinicopathologic and Molecular Study.
    Wen H; Zheng L; Zhang M; Pan X; Wang D; Qian J; Zhang X; Zhou Q; Chen N
    Int J Surg Pathol; 2024 Jun; 32(4):810-816. PubMed ID: 37715637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
    Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
    Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma].
    Chen S; Ban CR; Zhang XT; Chen YP; Ren CH; Chen H
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):155-161. PubMed ID: 38281783
    [No Abstract]   [Full Text] [Related]  

  • 17. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA3 aids in distinguishing fumarate hydratase-deficient renal cell carcinoma from papillary renal cell carcinoma.
    Liu Y; Dong Y; Gu Y; Xu H; Fan Y; Li X; Dong L; Zhou L; Yang X; Wang C
    Ann Diagn Pathol; 2022 Oct; 60():152007. PubMed ID: 35841867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fumarate hydratase deficient uterine leiomyoma: a clinicopathological and molecular analysis of 80 cases].
    Wang XX; Liu Y; Liu LC; Wang YX; Yang J; Hu AJ; Zhang B; Liu CR
    Zhonghua Bing Li Xue Za Zhi; 2023 Jun; 52(6):574-579. PubMed ID: 37263921
    [No Abstract]   [Full Text] [Related]  

  • 20. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.
    Chen YB; Brannon AR; Toubaji A; Dudas ME; Won HH; Al-Ahmadie HA; Fine SW; Gopalan A; Frizzell N; Voss MH; Russo P; Berger MF; Tickoo SK; Reuter VE
    Am J Surg Pathol; 2014 May; 38(5):627-37. PubMed ID: 24441663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.